Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 4;13(1):5.
doi: 10.1186/s13195-020-00740-0.

The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study

Affiliations

The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study

Amin Gharbi-Meliani et al. Alzheimers Res Ther. .

Abstract

Background: Approximately 25% of the general population carries at least one ε4 allele of the Apolipoprotein E (APOE ε4), the strongest genetic risk factor for late onset Alzheimer's disease. Beyond its association with late-onset dementia, the association between APOE ε4 and change in cognition over the adult life course remains uncertain. This study aims to examine whether the association between Apolipoprotein E (APOE) ε4 zygosity and cognition function is modified between midlife and old age.

Methods: A cohort study of 5561 participants (mean age 55.5 (SD = 5.9) years, 27.1% women) with APOE genotyping and repeated cognitive tests for reasoning, memory, and semantic and phonemic fluency, during a mean (SD) follow-up of 20.2 (2.8) years (the Whitehall II study). We used joint models to examine the association of APOE genotype with cognitive function trajectories between 45 and 85 years taking drop-out, dementia, and death into account and Fine and Gray models to examine associations with dementia.

Results: Compared to non-carriers, heterozygote (prevalence 25%) and homozygote (prevalence 2%) APOE ε4 carriers had increased risk of dementia, sub-distribution hazard ratios 2.19 (95% CI 1.73, 2.77) and 5.97 (95% CI 3.85, 9.28) respectively. Using data spanning 45-85 years with non-ε4 carriers as the reference, ε4 homozygotes had poorer global cognitive score starting from 65 years; ε4 heterozygotes had better scores between 45 and 55 years, then no difference until poorer cognitive scores from 75 years onwards. In analysis of individual cognitive tests, better cognitive performance in the younger ε4 heterozygotes was primarily attributable to executive function.

Conclusions: Both heterozygous and homozygous ε4 carriers had poorer cognition and greater risk of dementia at older ages. Our findings show some support for a complex antagonist pleiotropic effect of APOE ε4 heterozygosity over the adult life course, characterized by cognitive advantage in midlife.

Keywords: Alzheimer’s disease; Apolipoprotein E; Cognitive aging; Cohort study; Dementia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interest.

Figures

Fig. 1
Fig. 1
Flow chart of the study
Fig. 2
Fig. 2
Global cognitive score over the adult life course as a function of number of APOE ε4 alleles. Analysis are undertaken using joint models, using age as time scale (age, age2, and age3), and adjusted for sex, marital status, education level, occupation, and their interactions with time. a Global cognitive score trajectories according to the number of APOE ε4 alleles. b Difference in global cognitive score in APOE ε4 homozygotes and heterozygotes compared to non-ε4 carriers. Gray shaded intervals represent 95% confidence intervals of the estimates
Fig. 3
Fig. 3
Difference in standardized cognitive tests of memory (a), reasoning (b), semantic (c), and phonemic fluency (d) in APOE ε4 heterozygotes and homozygotes compared to non-ε4 carriers. Analysis are undertaken using joint models, using age as time scale (age, age2, and age3), and adjusted for sex, marital status, education level, occupation, and their interactions with time. Gray-shaded intervals represent 95% confidence intervals of the estimates

References

    1. Dumurgier J, Tzourio C. Epidemiology of neurological diseases in older adults. Rev Neurol (Paris). 2020;176:642–8. - PubMed
    1. Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele? Ann Hum Genet. 1999;63:301–310. doi: 10.1046/j.1469-1809.1999.6340301.x. - DOI - PubMed
    1. Saddiki H, Fayosse A, Cognat E, et al. Age and the association between apolipoprotein E genotype and Alzheimer disease: a cerebrospinal fluid biomarker-based case-control study. Plos Med. 2020;17:e1003289. doi: 10.1371/journal.pmed.1003289. - DOI - PMC - PubMed
    1. Conejero-Goldberg C, Gomar JJ, Bobes-Bascaran T, et al. APOE2 enhances neuroprotection against Alzheimer’s disease through multiple molecular mechanisms. Mol Psychiatry. 2014;19:1243–1250. doi: 10.1038/mp.2013.194. - DOI - PubMed
    1. Konijnenberg E, Tijms BM, Gobom J, et al. APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease. Alzheimers Res Ther. 2020;12:65. doi: 10.1186/s13195-020-00628-z. - DOI - PMC - PubMed

Publication types